GlassScriptPhysician profile
Dario Cardona
NPI 1770787434
$5,471.96
in general payments reported to CMS, 2019-2025
33 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $850 · 2021: $714 · 2022: $1,026 · 2023: $416 · 2024: $485 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,078.83 | 2019-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $503.09 | 2019-2022 | |
| Lilly USA, LLC | $408.73 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $394.55 | 2020-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.57 | 2019-2025 | Jardiance |
| Pfizer INC. | $350.10 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.55 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $277.85 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $239.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $207.71 | 2024-2025 | Voquezna |
| Abbott Laboratories | $171.90 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $139.68 | 2022-2024 | Vraylar |
| Biohaven Pharmaceutical Holding Company LTD. | $132.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.16 | 2021-2025 | |
| Dexcom, INC. | $119.26 | 2021-2024 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $117.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.17 | 2019-2023 | |
| Allergan, INC. | $56.79 | 2020 | |
| Amarin Pharma, INC. | $46.45 | 2020 | |
| Arbor Pharmaceuticals, INC. | $39.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.03 | 2020-2021 | |
| Mylan Specialty L.P. | $36.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.03 | 2019-2022 | |
| Esperion Therapeutics, INC. | $27.06 | 2021-2024 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $25.19 | 2019 | |
| Ge Healthcare | $24.42 | 2022 | |
| Genentech USA, INC. | $22.58 | 2019 | |
| Shield Therapeutics INC | $21.80 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.10 | 2021 | |
| Inspire Medical Systems, INC. | $20.93 | 2023 | Inspire |
| Inari Medical, INC. | $19.40 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Otsuka America Pharmaceutical, INC. | $15.12 | 2025 | Rexulti |
| Mannkind Corporation | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dario Cardona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.